Table 1.
Marker | COU-AA-301 study (N = 644) | ELM-PC4 study (N = 908) | ||
---|---|---|---|---|
| ||||
Median | (Range) | Median | (Range) | |
Baseline albumin | 4.1 | (2.9–4.9) | 4.4 | (2.5–5.4) |
Baseline ALK | 114.5 | (33–4617) | 96.0 | (35–3,281) |
Baseline CTC | 4.0 | (0–100) | 2.0 | (0–5,153) |
Baseline hemoglobin | 12.0 | (7.3–16.5) | 12.9 | (4.7–17.5) |
Baseline LDH | 215.0 | (84–3,373) | 186.0 | (67–1,868) |
Baseline PSA | 119.2 | (0.4–10,110) | 49.7 | (1.7–3,906) |
Week 13 CTC | 1.0 | (0–100) | 0 | (0–1,635) |
Week 13 PSA | 97.5 | (0.1–8,582) | 31.6 | (0–7682) |
Age | 70 | (42–95) | 71 | (49–89) |
Abbreviations: ALK, alkaline phosphatase; CTC, circulating tumor cells; LDH, lactate dehydrogenase; PSA, prostate-specific antigen.